吴俊华

时间:2019-06-24浏览:13331

博士研究生导师简介

姓名

吴俊华

研究方向

1.肿瘤免疫治疗

2.肿瘤学

3.药理学

联系方式

Email: wujunhua(at)nju.edu.cn

学术兼职:

Translational OncologySCI刊物编委


个人简介


1、工作简历

1998-2007  南京大学生科院  本科、博士

2007-2014  南京大学医学院  讲师

2014-2019  副教授

2019-      教授


2、科研情况简介

  • 主持国家自然科学基金面上项目、江苏省重点研发计划、江苏省自然科学基金和教育部博士点基金以及其他各类课题三十多项

  • 以第一作者或者通讯作者在Nature Communications等刊物发表SCI论文50余篇

  • 2015年发表的一篇关于肿瘤治疗新方法的文章被列为ESI高引用文章(学科前1%

  • 近五年SCI文章共计被SCI引用1000余次,篇均SCI引用次数近50

  • 参编专著1部:王军,吴俊华  先导化合物的优化 功能海洋生物分子—发现与应用(著作),科学出版社

  • 主译10万字的专注1部: 吴俊华、李方、裘吉人.《医学伦理》(译林出版社出版,原著为牛津大学出版社出版的Medical ethics


3、研究兴趣

1.肿瘤免疫治疗(尤其是溶瘤病毒和其他微生物介导的肿瘤免疫治疗)

2.肿瘤发生、发展的机制与治疗方法研究

3.化合物或者天然产物活性与功能的发现、评价与作用机制研究

代表性论文[5年通讯作者和第一作者]


  1. Wu JH#, Li PF#, Dong CL#, Jiang HT, Bin Xue, Gao X, Qin M, Wang W*, Bin Chen*, Cao Y*. Rationallydesigned synthetic protein hydrogels with predictable mechanical properties. Nature Communications. 2018, 9(1): 620. Doi: 10.1038/s41467-018-02917-6. IF: 17.694

  2.  Mao Xia#, Dongjun Luo#, Jie Dong#, Meihong Zheng, Gang Meng, Junhua Wu* and Jiwu Wei*. Graphene oxide arms oncolytic measles virus for improved effectiveness of cancer therapy. Journal of Experimental & Clinical Cancer Research (2019) 38: 408.IF: 12.658  *通讯作者

  3. Zhen Qu#, Junhua Wu#, Junyi Wu, Dongjun Luo, Chunping Jiang* and Yitao Ding*. Exosomes derived from HCC cells induce sorafenib resistance in hepatocellular carcinoma both in vivo and in vitro. Journal of Experimental & Clinical Cancer Research (2016) 35:159. #Co-first author  IF: 12.658

  4.  Hailin Zhang, Yonghui Zhang, Jie Dong, Shuguang Zuo, Gang Meng, Junhua Wu, Jiwu Wei. Recombinant adenovirus expressing the fusion protein PD1PVR improves CD8+ T cell mediated antitumor efficacy with long term tumor specific immune surveillance in hepatocellular carcinoma. Cellular Oncology,2021, 1243-1255  IF: 7.051  *通讯作者

  5.  Chun Xu#, Xian Lu#, Wei Liu, Anxian Chen, Gang Meng, Hailin Zhang, Binghua Li, Yonghui Zhang, Junhua Wu*, Jiwu Wei*. CD8+ T cells mediate the antitumor activity of frankincense and myrrh in hepatocellular carcinoma. Journal of Translational Medicine,2018, 16: 132.  IF: 8.44*通讯作者

  6. Junhua Wu, Aiping Chen, Meng Qin, Rong Huang, Guang Zhang, Bin Xue, Xiang Gao, Ying Li, Yi Cao and Wei Wang. Hierarchical construction of a mechanically stable peptide-graphene oxide hybrid hydrogel for drug delivery and pulsatile triggered release in vivo. Nanoscale2015 (7), 1655  DOI: 10.1039/C4NR05798H.   IF: 8.307  肝癌治疗新方法,该文章2016年被列为Web of Science高引用文章(学科前1%

  7.  Lu X#, Wo G#, Li B, Xu C, Wu J*, Jiang C*, Wei J*. The anti-inflammatory NHE-06 restores antitumor immunity by targeting NF-κB/IL-6/STAT3 signaling in hepatocellular carcinoma. Biomedicine & Pharmacotherapy, 2018, 102: 420-427.   IF: 7.419*通讯作者

  8. Weiwei Shi, Ding Ma, Yin Cao, Lili Hu, Shuwen Liu, Dongliang Yan, Shan Zhang, Guang Zhang, Zhongxia WangJunhua Wu and Chunping Jiang. SphK2/S1P Promotes Metastasis of Triple-Negative Breast Cancer Through the PAK1/LIMK1/Cofilin1 Signaling Pathway. Front. Mol. Biosci., 22 April 2021 https://doi.org/10.3389/fmolb.2021.598218.IF: 6.133*通讯作者

  9.  Hailin Zhang, Yonghui Zhang, Jie Dong, Chun Xu, Min Wei, Junhua Wu*and Jiwu Wei*. Recombinant oncolytic adenovirus expressing a soluble PVR elicits long-term antitumor immune surveillance. Molecular Therapy: Oncolytics Volume 20, 26 March 2021, Pages 12-22IF: 6.311  *通讯作者

  10. Yonghui Zhang, Junyi Wu, Hailin Zhang, Junhua Wu*and Jiwu Wei*. Extracellular Vesicles-Mimetic Encapsulation Improves Oncolytic Viro-Immunotherapy in Tumors With Low Coxsackie and Adenovirus Receptor. Frontiers in Bioengineering and Biotechnology 8 (2020) 574007.IF: 6.064*通讯作者

  11.  Aiping Chen#, Yonghui Zhang#, Gang Meng, Dengxu Jiang, Hailin Zhang, Meihong Zheng, Mao Xia1, Aiqin Jiang, Junhua Wu*, Christian Beltinger, Jiwu Wei*. Oncolytic measles virus enhances antitumour responses of adoptive CD8+NKG2D+ cells in hepatocellular carcinoma treatment. Scientific Reports, 2017, 7: 5170. DOI:10.1038/s41598-017-05500-z.IF: 4.996*通讯作者

  12.  Ding Ma#, Shuwen Liu#, Lili Hu, Qinyu He, Weiwei Shi, Dongliang Yan, Yin Cao, Guang Zhang, Zhongxia Wang, Junhua Wu*, Chunping Jiang. Single-cell RNA sequencing identify SDCBP in ACE2-positive bronchial epithelial cells negatively correlates with COVID-19 severity.J Cell Mol Med. 2021, 00:1–12  IF: 5.295  *通讯作者

  13.  Weibo Chen#, Junyi Wu, Weiwei Shi , Guang Zhang, Xuemin Chen, Anlai Ji, Zhongxia Wang*, Junhua Wu*, Chunping Jiang*.PRRX1 deficiency induces mesenchymal-epithelial transition through PITX2/miR-200–dependent SLUG/CTNNB1 regulation in hepatocellular carcinoma. Cancer Science, 2021, 112: 2158–2172.IF: 6.518*通讯作者

  14.  Weiwei Shi#, Shan Zhang#, Ding Ma, Dongliang Yan, Guang Zhang, Yin Cao, Zhongxia Wang*, Junhua Wu* and Chunping Jiang*. Targeting SphK2 Reverses Acquired Resistance of Regorafenib in Hepatocellular Carcinoma. Frontiers in Oncology , 2020, 10: 694IF: 5.738*通讯作者

  15.  Guang Zhang, Zhongxia Wang, Weibo Chen, Yin Cao, Junyi Wu, Guanghui Qiang, Anlai Ji, Junhua Wu*, Chunping Jiang*. Dual Effects of Gossypol on Human Hepatocellular Carcinoma via Endoplasmic Reticulum Stress and Autophagy. International Journal of Biochemistry & Cell Biology, 113 (2019) 48–57.  IF:5.652  *通讯作者

  16.  Wu JY#, Wang ZX#, Ma D, Qu Z, Wu JH*, Jiang CP*. Targeted co-delivery of Beclin 1 siRNA and FTY720 to hepatocellular carcinoma by calcium phosphate nanoparticles for enhanced anticancer efficacy. International Journal of Nanomedicine, 2018:13 1265–1280.IF: 7.033*通讯作者

承担科研项目[项目负责人]

目前主持的在研项目13,其中包括国家自然科学基金面上项目2和江苏省重点研发计划项目2项。合作申报获得立项的国家实验室、GFZB项目1。 目前个人可支配的科研经费合计500余万元

目前主持的在研的国家或者省级重点研发计划项目:

1、始于术中的溶瘤病毒Ad5-sPD1-PVR原位延续性免疫调节用于控制肿瘤术后复发

8197288820201-202312月,国家自然科学基金)

2、术中肿瘤原位放置装载溶瘤病毒的水凝胶用于控制肿瘤术后复发的技术开发

#BE202284020227-202512月,江苏省重点研发计划Primary Research & Developement Plan of Jiangsu Province

      3、阻断免疫检查点PD-1/PD-L1TIGIT的新型重组溶瘤腺病毒用于肝癌的治疗

#BE201870120187-202212月,江苏省重点研发计划Primary Research & Developement Plan of Jiangsu Province

    4、一种新的基于溶瘤腺病毒免疫治疗的综合治疗策略的研究

8227281920231-202612月,国家自然科学基金)